Innovent and Shenogen Enter into a Collaboration to Evaluate the Combination of Tyvyt (sintilimab injection) + SNG1005 for Advanced Cancer

 Innovent and Shenogen Enter into a Collaboration to Evaluate the Combination of Tyvyt (sintilimab injection) + SNG1005 for Advanced Cancer

Shots:

  • The companies enter into an agreement to evaluate the combination of Innovent’s Tyvyt with Shenogen’s SNG1005 for the patients with advanced cancer 
  • Shenogen has in-licensed SNG1005 and has exclusive rights to develop & commercialize it in Greater China. SNG1005 has completed multiple P-II trials in the US with an approved NMPA’s IND application of P-II/III for breast cancer carcinoma brain metastases
  • Tyvyt is an Ig-G4 mAb targeting PD-1, blocks PD-L1 pathway thus reactivates T-cells to kill cancer cells and has received NMPA’s approval for r/r cHL in Dec’18. SNG1005 is a first nab-paclitaxel therapeutic that binds to LRP1 and can penetrate the blood brain barrier

Click here to­ read full press release/ article | Ref: PRNewswire | Image: GMP News

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post